within Pharmacolibrary.Drugs.ATC.J;

model J01GB12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.024666666666666667,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.00026000000000000003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Arbekacin is an aminoglycoside antibiotic primarily used for the treatment of infections caused by multi-drug resistant Gram-negative bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA) and certain resistant strains of Pseudomonas aeruginosa. It is used mainly in Japan and some Asian countries for serious infections when other antibiotics may fail. It is not widely approved or used in Western countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult patients with infections; intravenous administration.</p><h4>References</h4><ol><li><p>Funatsu, Y, et al., &amp; Betsuyaku, T (2014). Pharmacokinetics of arbekacin in bronchial epithelial lining fluid of healthy volunteers. <i>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</i> 20(10) 607–611. DOI:<a href=&quot;https://doi.org/10.1016/j.jiac.2014.05.007&quot;>10.1016/j.jiac.2014.05.007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24973909/&quot;>https://pubmed.ncbi.nlm.nih.gov/24973909</a></p></li><li><p>Lakota, EA, et al., &amp; Rubino, CM (2019). Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution. <i>Antimicrobial agents and chemotherapy</i> 63(8) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.00267-19&quot;>10.1128/AAC.00267-19</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31182524/&quot;>https://pubmed.ncbi.nlm.nih.gov/31182524</a></p></li><li><p>Kobuchi, S, et al., &amp; Sakaeda, T (2022). Comparing the pharmacokinetics and organ/tissue distribution of anti-methicillin-resistant . <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 52(6) 583–590. DOI:<a href=&quot;https://doi.org/10.1080/00498254.2022.2098201&quot;>10.1080/00498254.2022.2098201</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35815433/&quot;>https://pubmed.ncbi.nlm.nih.gov/35815433</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01GB12;
